Aducanumab-avwa
Aducanumab-avwa
Aducanumab-avwa (pronounced as ad-yoo-KAN-yoo-mab-av-wa) is a monoclonal antibody medication used for the treatment of Alzheimer's disease.
Etymology
The name "Aducanumab-avwa" is derived from the generic name "Aducanumab", which is a type of monoclonal antibody specifically designed to target and remove beta-amyloid plaques in the brain, which are a common hallmark of Alzheimer's disease. The suffix "-avwa" is a regulatory designation indicating the specific formulation and manufacturing process of the drug.
Usage
Aducanumab-avwa is used in the treatment of Alzheimer's disease. It is administered via intravenous infusion. The drug works by binding to beta-amyloid plaques in the brain and promoting their removal, which can help to slow the progression of Alzheimer's disease.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Beta-amyloid plaques: Clumps of beta-amyloid protein that accumulate in the brains of people with Alzheimer's disease.
- Alzheimer's disease: A progressive brain disorder that affects memory, thinking skills, and the ability to carry out simple tasks.
- Intravenous infusion: A method of delivering medication or other substances directly into a vein.
External links
- Medical encyclopedia article on Aducanumab-avwa
- Wikipedia's article - Aducanumab-avwa
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski